Traditional pathway analysis map single nucleotide polymorphisms (SNPs) to genes according to physical position, which lacks sufficient biological bases. Here, we incorporated genetics of gene expression into gene-and pathway-based analysis to identify genes and pathways associated with lung cancer risk. We identified expression-related SNPs (eSNPs) in lung tissues and integrated these eSNPs into three lung cancer genome-wide association studies (GWASs), including 12,843 lung cancer cases and 12,639 controls. We used SKAT-C for gene-based analysis, and conditional analysis to identify independent eSNPs of each gene. ARTP algorithm was used for pathway analysis. A total of 374,382 eSNPs in the GWAS datasets survived quality control, which were mapped to 5,084 genes and 2,752 pathways. In the gene-based analysis, nine genes showed significant associations with lung cancer risk. Among them, TP63 (3q28), RP11-650L12.2 (15q25.1) and CHRNA5 (15q25.1) were located in known lung cancer susceptibility loci. We also validated two newly identified susceptibility loci (RNASET2 and AL133458.1 in 6q27, and MPZL3 in 11q23.3). Besides, DVL3 (3q27.1), RP11-522I20.3 (9q21.32) and CCDC116 (22q11.21) were identified as novel lung cancer susceptibility genes. Pathway analysis showed that pathways involved in protein structure, the Notch signaling pathway and the nicotinic acetylcholine receptor-related pathways were associated with lung cancer risk. Combing eSNPs, gene-and pathway-based analysis identifies novel lung cancer susceptibility genes, which serves as a powerful approach to decipher biological mechanisms underlying GWAS findings.
Introduction
Lung cancer was the most frequently diagnosed cancer in the world. There were approximately 1.8 million new lung cancer cases worldwide in 2012. 1 In the United States, 224,390 incident lung cancer cases and 158,080 lung cancer deaths were projected to occur in 2016. 2 In China, there were approximately 733 thousand lung cancer cases and 610 thousand lung cancer deaths in 2015. 3 Lung cancer was the leading cause of cancer-related death in both countries. The development of lung cancer involves the interplay between genetic and environmental factors. Tobacco smoking has been confirmed to be a major risk factor for lung cancer. Besides environmental factors, inherited genetic factors also play important roles in lung cancer development. 4 Genome-wide association studies (GWASs) have been proven to be a powerful approach in genetic analysis of complex diseases and traits. Dozens of single nucleotide polymorphisms (SNPs) associated with lung cancer risk had been identified by GWASs. 5 However, the information provided by GWAS remains inadequate. GWAS lack the power to detect potentially genuine signals with small effect. 6 And there were no formal methods for identifying the causative variants of a given disease. Moreover, the biological mechanisms underlying the genotype-phenotype association were usually unclear in previous GWASs. 7 Gene-and pathway-based analyses are complementary approaches to GWAS. These approaches could test whether the joint effect for a group of variants located in a gene or functionally related gene sets are associated with a trait or disease. 8 There is growing evidence that disease susceptibility genes usually interact with one another in biological pathways, which will contribute to disease etiology. 9 Thus integrating prior knowledge of genes and pathways may increase the power to identify disease-related loci. Several approaches were proposed to map SNPs to a specific gene based on physical position. 8, 10 However, most SNPs may not represent functional variants of the nearest gene, 11 because variants may regulate distant genes by chromatin interaction. 12 Recently, Zhong et al. developed an approach to integrate expression-related SNPs (eSNPs) into pathway analysis using GWAS data. They demonstrated that the approach could provide additional power to unravel biologically important pathways. 11 Afterwards, researchers applied this approach to GWAS of basal cell carcinoma (BCC) and gained more biologically meaningful insights into BCC development. 13 In our study, we utilized eSNPs of lung tissues from GTEx database, and conducted gene-and pathway-based analysis for lung cancer GWAS. We carried out our analysis as follows: (i) gene-based analysis was conducted to identify lung cancer susceptibility genes (ii) for eSNPs associated with promising genes, approximate joint and conditional analysis was applied to identify independent SNPs of each gene; (iii) after collecting well-curated lists of pathways, ARTP pathway analysis was applied to investigate pathways that might be involved in lung cancer risk. A flow chart of study design is shown in Figure 1 . Such a hierarchical approach integrated three levels of evidence (i.e., evidence from the SNP-, geneand pathway-level) to decipher novel biological mechanisms underlying lung cancer development. We also used replication data sets to reduce false-positive findings. After application of our approach to lung cancer GWAS, we discovered novel susceptibility genes that would otherwise remain undetected in variant-by-variant analysis.
Material and Methods

Study populations
Three existing GWASs including 12,843 lung cancer cases and 12,639 controls were used in our study: (i) the GWAS conducted by our group in Nanjing Medical University (NJMU) (2,331 cases and 3,077 controls), 14 (ii) the GWAS of the Female Lung Cancer Consortium in Asia (FLCCA) (4,796 cases and 3,741 controls), 15 (iii) the GWAS conducted by the National Cancer Institute (NCI) (5,716 cases and 5,821 controls). 16 FLCCA and NCI data were obtained from the NCBI database of Genotypes and Phenotypes (dbGaP). Detailed information of these GWASs was provided in Supplementary Note. Basic characteristics and clinical features of participants involved in each study are summarized in Table S1 . The study was conducted after Human Experimentation Review. Informed consent was obtained from all participants and study protocols were approved by the ethical review boards of each institution.
Quality control and imputation of GWAS data
Based on the quality control procedure of GWAS data, we excluded individuals with call rates <95%, familial
What's new? Single nucleotide polymorphisms (SNPs) can be mapped to genes based on physical position, though this approach may overlook biologically relevant aspects of SNPs. In our study, information from gene expression was integrated with gene-and pathway-based analyses to discover genetic variants and pathways linked to lung cancer. While four lung cancer susceptibility loci were validated and three new lung cancer susceptibility genes identified using gene-based analysis, pathway-analysis led to the discovery of nine pathways associated with lung cancer risk. The findings suggest that integration of expressionrelated SNPs with genome-wide analytical approaches can facilitate the discovery of disease-associated genes and mechanisms.
relationships or extreme heterozygosity rates. SNPs were ruled out for those with call rates <95%, minor allele frequencies (MAFs) <0.05 or p < 1 3 10 26 for Hardy-Weinberg equilibrium (HWE). We phased the haplotypes with Shapeit v2. 17 After that, we performed imputations on the NJMU, FLCCA and NCI GWASs with IMPUTE2 18 for >2 million markers based on data from the 1,000 Genomes Project (the Phase III integrated variant set release, across 2,504 samples). SNPs with imputation quality score INFO <0.4, MAF <0.01 or HWE p < 1 3 10 26 were excluded from the analysis.
Identification of eSNPs in lung tissue
We identified eSNPs in lung tissues based on the GenotypeTissue Expression (GTEx) database (V6 release), which provided a resource to study human gene expression and its relationship to genetic variation. 19 DNA samples were genotyped on Illumina's Human Omni 5 M and Illumina's Human Omni 2.5 M. Variants of SNPs and indels were imputed based on the 1,000 Genomes Project Phase I version 3 reference panel. A series of standard quality control approaches were applied to the genotype data both prior to and after imputation. Gene expression data were obtained using Affymetrix Expression Array or Illumina TruSeq RNA sequencing. There were 278 lung tissues with both genotype and gene expression data. Linear regression analysis was applied to assess correlation of SNP-gene pairs by assuming an additive model, which included genotyping principal components (PCs), genotyping array factors, PEER factors and gender as covariates. We extracted significant SNP-gene pairs (cis-eQTLs, FDR < 0.05) from the GTEx Analysis V6 release (http://www.gtexportal.org/home/datasets). (1) Data preparation. Expression-related SNPs (eSNPs) were identified from significant SNP-gene pairs (cis-eQTLs, FDR <0.05) in lung tissues of the GTEx database (V6 release). Standard quality control and imputation were performed on the three GWAS datasets, and the eSNPs were extracted from GWAS datasets. (2) Gene-and pathway-based analyses. Gene-based analysis was conducted using SKAT-C. A total of nine genes with FDRs <10% in the combined dataset were considered as significant. For pathway analysis, gene-set collections from the MSigDB, including 2,752 pathways from BioCarta, Reactome, MicroRNA Targets, GO and KEGG databases, were downloaded. Gene-based p-values were integrated into the adaptive rank truncated product (ARTP) algorithm to compute p-values for each pathway, during which 10,000 permutations were performed. Nine pathways with (1) p-values <0.01 in the combined dataset and (2) p-values <0.05 in at least two GWASs were considered as significant. (3) Functional annotation and conditional analysis for eSNPs within nine significant genes. A total of 817 eSNPs were associated with the nine lung cancer susceptibility genes. Functional annotation of these eSNPs was performed using data from ENCODE project and RegulomeDB. Approximate joint and conditional analysis was conducted to eSNPs within each significant gene. The multiple regression R 2 of the testing SNP on the selected SNPs was set to be 0.1 during the model selection procedure. And the threshold p-values of 0.001 were adopted to identify significant hits. Eight independent eSNPs were identified. The number of samples or eSNPs listed in the figure all satisfied the quality control procedures of GWAS data. [Color figure can be viewed at wileyonlinelibrary.com]
Gene-based analysis with lung cancer risk
The aim of gene-based analysis was to identify genes with particular importance to lung cancer risk. We mapped eSNPs to a gene if they were associated with expression levels of that gene (association FDR < 0.05 according to GTEx database). A total of 5,084 genes with at least 5 eSNPs were retained for gene-based analysis. For GWAS data of NJMU, FLCCA, NCI and a combination of these three datasets, gene-based analysis was conducted using SKAT-C (R package SKAT, version 1.1.2). The SKAT-C is an improved version of sequence kernel association test (SKAT), which performed combined sum test of rare-and common-variant effects. 20 SKAT-C tests for association between groups of SNPs and a phenotype by aggregating the weighted variance-component score statistics for each SNP within a group using kernel function. We adjusted for age, gender, smoking status or smoking pack years, and principal components when appropriate. To correct for multiple testing, Benjamini-Hochberg method was used for false discovery rate (FDR) estimation. We set a significance cutoff at 10% FDR in the combined dataset.
Approximate joint and conditional association analysis and functional annotation of eSNPs
Since multiple eSNPs associated with a specific gene usually locate in a single linkage disequilibrium (LD) block, we performed approximate joint and conditional association analysis to identify independent eSNPs associated with lung cancer risk using genome-wide complex trait analysis (GCTA). 21 The multiple regression R 2 of the testing SNP on the selected SNPs was set to be 0.1 during the model selection procedure. Age, gender, smoking status/smoking pack years and principal components were adjusted when appropriate during conditional analysis. The threshold p-values of 0.001 were adopted to identify significant hits. For eSNPs within promising genes, we performed functional annotation using ANNOVAR. 22 The functional effects of missense variations were predicted using the SIFT 23 and PolyPhen 24 databases. The following regulatory features from the Encyclopedia of DNA Elements (ENCODE) were also used for annotation: histone modification sites (H3K27ac and H3K4me3), DNase I hypersensitivity sites (DHS) and transcription factor binding sites (TFBS). We downloaded these features measured in A549 cell lines from the UCSC genome browser. 25 Pathway analysis with ARTP Gene-set collections were downloaded from the Molecular Signatures Database website (MSigDB, version 5.0, http://software.broadinstitute.org/gsea/downloads.jsp). 26 We included pathways from BioCarta (217 pathways), Reactome (674 pathways), MicroRNA Targets (221 gene-sets), GO (1,454 GO terms) and KEGG (186 pathways). Pathway analysis was performed using the adaptive rank truncated product (ARTP) test (R package ARTP, version 2.0.4). The ARTP method utilized a highly efficient permutation algorithm to determine whether the joint effects of genes within a pathway were significantly associated with diseases or traits. 27 We utilized p-values generated by SKAT-C and performed 10,000 permutations. The ARTP algorithm was applied to computing test statistic as well as p-values for each pathway. Pathways were considered significant when they had (1) p-values <0.01 in the combined dataset and (2) p-values <0.05 in at least two GWASs.
Co-expression and KEGG enrichment analysis
We obtained the expression data of 56,318 genes for 320 normal lung tissues from the GTEx database (V6 release). We performed genome-wide expression correlation analysis using linear regression model to identify co-expressed genes. Significant co-expressed genes that satisfied the Bonferroni correction were used for KEGG enrichment analysis, which was implemented in R package "clusterProfiler." 28 
Results
We identified 455,995 eSNPs in lung tissues from the GTEx database. Among them, 374,382 eSNPs were available from GWASs after quality control. These eSNPs were mapped to 5,084 genes. In the 2,752 pathways of the five pathway databases, including BioCarta, Reactome, MicroRNA Targets, GO and KEGG, a total of 2,154 (42.37%) genes and 191,429 (51.13%) eSNPs were covered.
Gene-based analysis
In the gene-based analysis, we found 9 genes associated with lung cancer risk at the predefined significance level of 10% FDR in the combined dataset (Table 1) . Among them, TP63 (3q28), RP11-650L12.2 (15q25.1) and CHRNA5 (15q25.1) were located in known susceptibility loci that had been identified by previous lung cancer GWASs.
5 CHRNA5 and RP11-650L12.2 were located in the same chromosome region, and the expressions of these two genes in lung tissues were positively correlated with each other in a relative strong scale (r 2 5 0.93, p < 0.001) (Fig. S1 ). KEGG enrichment analysis showed that genes co-expressed with RP11-650L12.2 and CHRNA5 were almost enriched in the same pathways, including cell cycle, antigen processing and presentation, DNA replication and spliceosome (Table S2) .
When our study was in preparation, a large-scale lung cancer genetic association study in European populations was published and reported 10 new susceptibility loci. 29 Interestingly, we validated two of these newly identified loci, namely 6q27 (RNASET2; AL133458.1) and 11q23.3 (MPZL3). The pseudogene AL133458.1 and the coding gene RNASET2 were both located at 6q27 with a 2.3 kb overlapping region. In our gene-based analysis, associations of RNASET2 and AL133458.1 with lung cancer risk reached nominal significance in Europeans (p 5 7.63 3 10 23 and 6.74 3 10 23 for RNASET2 and AL133458.1, respectively) ( Table 1 ). When we Cancer Genetics and Epigenetics combine data of Asian populations (NJMU and FLCCA GWAS), the associations were also nominally significant (p 5 7.88 3 10 23 and 9.56 3 10 23 for RNASET2 and AL133458.1, respectively). Co-expression analysis showed that the expression of AL133458.1 was significantly correlated with RNASET2 in lung tissues (r 2 5 0.49, p < 0.001) (Fig. S1 ). Chromosome region 11q23.3 was identified as a susceptibility locus for lung adenocarcinoma (lung ADC) in Europeans. Our results showed that the association of MPZL3 reached nominal significance in both Asian and European populations (p 5 1.39 3 10 24 in pooled analysis of NJMU and FLCCA GWAS, and p 5 3.16 3 10 23 in NCI GWAS) ( Table  1) . In subgroup analysis, the association of MPZL3 with lung cancer risk was more significant in lung ADC than in lung squamous cell carcinoma (lung SqCC) (p 5 8.23 3 10 26 and 7.37 3 10 22 in lung ADC and lung SqCC, respectively) (Table S3 ).
In addition to the genes described above, we identified CCDC116 (22q11.21), DVL3 (3q27.1) and RP11-522I20.3 (9q21.32) as novel lung cancer susceptibility genes. They reside on different chromosome regions, and seem to represent independent signals ( Table 1, Table S3 ).
Variants within lung cancer susceptibility genes
A total of 817 eSNPs were associated with the 9 identified lung cancer susceptibility genes (Table S4) . After functional annotation, 49.57% (n 5 405) of the eSNPs fall within introns, and 40.39% (n 5 330) resided in intergenic regions. Among the 13 exonic SNPs, rs1793174 and rs17121881 in JAML, rs843358 in EIF2B5, rs16969968 in CHRNA5 and rs2298428 in YDJC were missense variants. In total, 11.75% (n 5 96) of the 817 eSNPs fall within promoters marked by H3K4me3, 9.30% (n 5 76) in enhancers marked by H3K27ac, 1.47% (n 5 12) in DNase I hypersensitivity sites, and 5.75% (n 5 47) in transcription factor binding sites according to ChIP-seq data in A549 cell lines (Table S4) .
Since multiple eSNPs in LD could be detected for a given gene, we performed conditional analysis to identify independent signals within each gene. As a result, each gene had only one independent signal except for CHRNA5 and RP11-650L12.2, which showed two independent signals (Table 2, Fig. S2 ). SNP rs1051730 was the top signal of CHRNA5 and RP11-650L12.2. When adjusting for rs1051730, we detected a second significant independent signal tagged by rs1847529, which was in LD (r 2 5 0.21 in Europeans) with rs1051730 (Table S5) ) and rs11216826 (linkage disequilibrium r 2 > 0.9 with rs1056562 reported by McKay et al. 29 ), represented the known loci of lung cancer. Besides, rs444210 (independent eSNP at RNA-SET2 and AL133458.1), was in linkage disequilibrium with the newly identified lung cancer susceptibility SNP rs6920364 29 (linkage disequilibrium r 2 5 0.81 and 0.33 in European and Asian populations, respectively) (Table S5) .
To assess heterogeneity in the genetic effects, we calculated the index of heterogeneity (I 2 ) and p-values for Cochran's Q statistic for independent eSNPs. We did not observe significant heterogeneity among studies or between histological types in the two newly identified lung cancer susceptibility loci reported by McKay et al. (6q27 and 11q23.3 ) and the three novel susceptibility loci (3q27.1, 9q21.32 and 22q11.21) (Tables S6 and S7 ). Nevertheless, genetic effects of (Table S7) .
Pathway analysis
Pathway analysis using ARTP algorithm identified nine pathways that were significantly associated with lung cancer risk ( Table 3 , Table S8 ). Based on overlapping eSNPs, clustering analysis divided the nine pathways into three clusters, including three pathways involved in protein structure, the Notch signaling pathway, and five pathways related to nicotinic acetylcholine receptor (Supplementary Notes, Table S9 , and Fig.  S3) . Notably, the significance of the three pathways involved in protein structure and the Notch signaling pathway was largely driven by TP63, while the significance of the other five pathways related to nicotinic acetylcholine receptor was mostly driven by CHRNA5; as TP63 and CHRNA5 were the only genes among the nine pathways that reached statistical significance at 10% FDR in the combined dataset (Table  S10) .
Discussion
In our study, we incorporated eSNPs from the GTEx database into genome-wide gene-and pathway-based analyses. The analysis, which involved 5,084 genes and 2,752 pathways, was carried out on three large-scale lung cancer GWASs. Approximate joint and conditional analysis was performed on eSNPs within significant genes to identify independently associated signals. We validated four lung cancer susceptibility loci (3q28, 6q27, 11q23.3 and 15q25.1). In addition, we identified three novel susceptibility genes (CCDC116, DVL3 and RP11-522I20.3). Pathway analysis identified nine pathways involved in protein structure, the NOTCH signaling, and nicotinic acetylcholine signal transduction, which might represent the key biological mechanisms in the development of lung cancer. TP63 and CHRNA5 are well-recognized lung cancer susceptibility genes.
5 CHRNA5 encodes a nicotinic acetylcholine receptor subunit and is involved in nicotinic acetylcholine signal transduction. Nicotinic acetylcholine receptors (nAChRs) were ubiquitously expressed in mammalian cells, including bronchial and bronchiolar epithelial cells, pulmonary neuroendocrine cells and cancer cells. 31 Nicotine and its metabolites could alter the signaling of nAChRs, resulting in stimulation of cancer cells. 32 Several subunits of nAChRs jointly increase the release of stress neurotransmitters, which activate b-adrenergic receptors to release vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) 
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Abbreviations: OR, odds ratio; 95%CI, 95% confidence interval. Effect allele/other allele. 3 Age, gender, smoking pack years and the first principal component (PCA) were adjusted in NJMU GWAS; age and three significant PCAs were adjusted in FLCCA GWAS; age, gender, study and the first 10 PCAs were adjusted in NCI GWAS. 4 Association results of independently effective eSNPs in the combined data, with adjustment of age, gender, study and the first 10 PCAs.
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and contribute to initiation and progression of numerous cancers including lung cancer.
33-35
TP63 encodes a member of the tumor suppressor p53 (also known as TP53) family of transcription factors, which take on functions in development, DNA damage response via apoptosis and cell cycle arrest, and immortalization and oncogenesis.
36 TP63 is involved in the Notch signaling pathway. The involvement of Notch signaling in lung cancer has been well explored. A transgenic mouse model with activated Notch1 overexpression in the alveolar epithelium showed alveolar hyperplasia and pulmonary adenomas. When engineered to express activated Notch1 and Myc, the mice developed adenocarcinoma. 37 In Kras-driven mouse models and human non-small cell lung cancer (NSCLC), Notch3 played a nonredundant role in self-renewal of tumor cells.
38 TP63 is also involved in pathways that modulate protein oligomerization (including tetramerization and homo-oligomerization), which has been shown to be crucial for their function. For example, tetramerization of p53 is essential for its binding to DNA. 39 Mutations in the p53 tetramerization domain have been reported in patients with Li-Fraumeni syndrome, a rare disease presented as early cancer onset.
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MPZL3 (myelin protein zero-like 3) acts downstream of several known transcriptional regulators, including p63. It is essential for normal epidermal differentiation. 41 MPZL3 was located in mitochondria, where it interacted with FDXR and increased reactive oxygen species (ROS) to drive epidermal differentiation. 42 MPZL3 was downregulated in cutaneous squamous cell carcinoma. 42 However, the effect of MPZL3 on lung cancer risk remains unknown. The risk allele of rs11216826 was associated with a decreased expression of MPZL3, indicating the protective role of MPZL3 in lung cancer development. Genes that co-expressed with MPZL3 were enriched in biological processes such as nucleotide excision repair. Nucleotide excision repair eliminates structurally unrelated DNA lesions. Defects in nucleotide excision repair leads to the genome-wide accumulation of DNA lesions, which can be bypassed by error-prone translesion DNA polymerases. Lesion bypass promotes cell survival and increases mutagenesis, which can be involved in carcinogenesis. 43 These evidences suggest that MPZL3 acts as lung cancer susceptibility gene possibly by modulation of DNA repair capacity.
RNASET2 (ribonuclease of the T2 family) is located on chromosome 6q27. It has been implicated as a tumor suppressor in ovarian cancer. 44 Liu et al. transfected SV40 immortalized cell line with RNASET2. They found forced expression of RNASET2 in immortalized cells reduced colony forming efficiency, anchorage independence and growth rate of cells. 45 Acquati F et al. found that extracellular RNASET2 could modify cellular microenvironment by the recruitment of immunocompetent cells of the monocyte/macrophage lineage, which might be a critical step in RNASET2-mediated tumor suppression. 46 Consistent with previous findings, KEGG enrichment analysis showed that genes co-expressed with RNASET2 were enriched in pathways such as B cell receptor signaling and primary immunodeficiency, which were involved in immune function. But our results indicated a tumor promoting role of RNASET2 in lung carcinogenesis, for the protective allele of rs444210 was associated with decreased expression of RNASET2. Although immune surveillance plays an important role in preventing tumorigenesis, the link between chronic immune activation and lung cancer is well established. 47 Inflammation could contribute to 1 The number of genes in the pathway according to the MSigDB (version 5.0). 2 The number of genes that has expression-related SNPs (eSNPs) in GWAS data. 3 The number of eSNPs within each pathway. 4 p-Values were derived from ARTP algorithms based on 10,000 permutations.
carcinogenesis by supplying bioactive molecules to the tumor microenvironment, including growth factors that sustain proliferative signaling, survival factors that limit cell death and proangiogenic factors. 48 Further functional studies are warranted to elucidate the role of RNASET2 in lung carcinogenesis.
DVL3 belongs to the dishevelled (Dvl) family protein, which is a cytoplasmic scaffold protein that bridges the receptors and downstream signaling molecules. The relocation of the cytoplasmic Dvl to the plasma membrane was involved in initiating the Wnt/b-catenin and planar cell polarity pathways. 49 Deregulation of Wnt cascade has been implicated in cancer cell maintenance and growth. 50 Our results showed the risk allele of rs1969253 was associated with a decreased expression of DVL3, indicating a tumor suppressive role. Further functional experiments are warranted to unravel the underlying molecular mechanisms for DVL3, as well as the other promising genes, in lung carcinogenesis.
AL133458.1 is a pseudogene located in 6q27 and is significantly co-expressed with RNASET2. RP11-522I20.3 is a long non-coding RNA (lncRNA) located near UBQLN1, which encodes a protein that mediates the proteasomal degradation of proteins. Genes co-expressed with RP11-522I20.3 were enriched in pathways such as mismatch repair, nucleotide excision repair and base excision repair. Similar to RP11-522I20.3, genes co-expressed with CCDC116 also showed enrichment in DNA repair-related pathways. However, the biological function of these genes on lung cancer development remains elusive.
Our study in lung cancer identified two known susceptibility loci (3q28 and 15q25.1), validated two newly identified susceptibility loci (6q27 and 11q23.3), and identified three novel cancer susceptibility genes (DVL3 in 3q27.1, RP11-522I20.3 in 9q21.32 and CCDC116 in 22q11.21). Associations of independent eSNPs in the two validated loci (6q27 and 11q23.3) and the three novel loci (3q27.1, 9q21.32 and 22q11.21) did not show significant heterogeneity between populations. However, we were unable to identify susceptibility genes that are specific to Asian populations since genetics of gene expression study using lung tissues of Asians were not available. Another limitation of our study was that the proportion of genes that could be represented by eSNPs was limited. It was partly due to the small sample size of GTEx data, which may not be powered enough to identify all relevant eSNPs. And SNPs might modify disease risk through other mechanisms such as epigenetics. Therefore, a more comprehensive functional annotation of SNPs in diseaserelated tissues from various populations is needed. Further studies with larger sample size are needed to verify our findings. And additional experimental studies are warranted to elucidate the mechanisms of these genes and pathways in lung cancer initiation and progression.
